Summary. The inflammatory response and the activation of coagulation are two important responses in a host's defense against infection. These mechanisms do not work independently, but cooperate in a complex and synchronous manner. Recent research has also shed light on the critical role of thrombus formation, which prevents the dissemination of microorganisms. The cellular components of blood vessels, i.e. leukocytes, platelets, erythrocytes, and vascular endothelial cells, play significant roles in the development of thrombi in combination with activation of the coagulation system. In addition to the cellular components, alarmins such as histones and highmobility group box 1, microparticles and secreted granule proteins are all important for clot formation. In this summary, we review the pathophysiology of sepsis-induced coagulopathy and the role of cellular components and critical factors released from damaged cells. In addition, we review important therapeutic approaches that have been developed, are under investigation and are currently available in certain countries, including antithrombin, recombinant thrombomodulin, anti-Toll-like receptor 4 therapy, anti-damage associated molecular pattern therapy, and hemoadsorption with a polymyxin B-immobilized fiber column.
Introduction
Coagulation system activation and subsequent thrombus formation occur in most patients with sepsis [1] . According to a nationwide registry study, approximately half of all patients treated for sepsis in the intensive care unit (ICU) have disseminated intravascular coagulation (DIC) complications [2] , according to the Japanese Association for Acute Medicine (JAAM) DIC criteria [3] . As the JAAM DIC criteria were designed for the diagnosis of DIC at a relatively early stage of coagulopathy, the reported incidence may be higher than in other reports, but coagulation disorders are common in patients with sepsis.
During DIC, both blood cells and vascular endothelial cells play key roles, together with coagulation factors, as part of the underlying pathophysiology. The clotting cascade is initiated by the expression of tissue factor (TF) on monocytes, platelets, endothelial cells, and possibly neutrophils [4, 5] . A complex composed of TF and activated factor VII (FVIIa) catalyzes the conversion of inactive FX to its active form, which leads to further activation of coagulation. Recent reports indicate that the interaction between inflammation and coagulation plays a pivotal role in the pathophysiology of sepsis [1] . Together with the activation of immune cells, thrombi are formed as a first-line host immune defense in the vasculature. It is of note that patients who were heterozygous for the FV Leiden mutation, a thrombogenic variant, had better survival outcomes than those who were negative for the FV Leiden mutation, and this result was confirmed in an animal study [6] . However, systemic thrombosis can also exacerbate sepsis-induced organ dysfunction [7] . The sequential activation of coagulation ultimately leads to DIC, which can result in a worsening of organ dysfunction and death. The mortality rate of septic DIC patients is approximately twice that of septic patients without DIC [8] . Effective management modalities in addition to the innate immune responses have been developed, including surgery, drainage, and antibiotics. However, growing data suggest that additional management of the altered coagulation of DIC is a potential option for improving morbidity and mortality. Recent studies have reported additional therapeutic approaches for sepsis-induced coagulopathy (SIC) [9, 10] that also focus on determining the timing and management strategies, and the role of blood cells and vascular endothelial cells [11] . In this review, we introduce recent findings regarding the pathophysiology of sepsisinduced microthrombosis, particularly the associations among various cells in blood vessels.
Leukocytes
In 2013, Engelmann et al. [6] coined the word 'immunothrombosis', which describes an innate immune response induced by the formation of thrombi in microvessels and supported by immune cells together with specific thrombosis-related molecules. Immunothrombosis facilitates the recognition, entrapment and disposal of pathogens, thereby protecting host integrity without inducing major collateral damage as long as it functions properly. However, when these reactions occur systemically and are sustained for a long period, they can lead to DIC followed by multiorgan failure and even death.
Monocytes and macrophages, together with platelets, have long been recognized as the major blood cells for activation of the coagulation system. However, the active involvement of neutrophils has been realized only recently [12] (Fig. 1) . For example, neutrophil depletion leads to the attenuation of thrombotic manifestations [13] . A very significant event in neutrophil research was the discovery of neutrophil extracellular traps (NETs), and the observations that the extracellular components of neutrophils formed by DNA, histones and granule constituents have procoagulant and prothrombotic effects have attracted much attention [14, 15] . The extracellular delivery of TF by NETs favoring FVIIa-mediated thrombin generation [13] and the polyanionic surface of NETs associated with contact-phase protein-mediated intrinsic pathway activation lead to massive clot formation in the vasculature [14] . Although neutrophils have been reported to be unlikely to produce TF by themselves, Kambas et al. [16] observed TF inclusion in autophagosomes prior to extracellular delivery in NETs, and suggested autophagic involvement in that process. The above-mentioned thrombogenic reaction can be induced through means other than neutrophil cell death. In addition to NETosis, the process by which active neutrophil death results in the ejection of NETs, viable neutrophils also expel NETs consisting of both nuclear and mitochondrial DNA in a non-cell-lytic manner [17, 18] .
In addition to causing microcirculatory disturbances, thrombin generation by leukocytes has been implicated in the induction of further inflammation through the activation of protease-activated receptors (PARs) [19] . PARs are G-protein-coupled membrane receptors expressed on a variety of cells, including platelets, leukocytes, and endothelial cells. Thrombin and other coagulation factors, such as FVIIa and activated FX, activate various cells and regulate their behavior through the activation of these receptors. For example, PAR-1 is activated when thrombin binds to and cleaves its N-terminal exodomain to unmask a new receptor N-terminus. This new N-terminus then serves as a tethered peptide ligand, binding intramolecularly to the body of the receptor to effect transmembrane signaling [20] . PARs are also activated by other serine proteases such as elastase and cathepsin G, which are served by NETs (they are the components of NETs); therefore, neutrophils also induce proinflammatory and prothrombotic responses to other cells through these granule proteins [21] . For instance, the activation of PARs upregulates the endothelial expression of TF, the mobilization of Weibel-Palade bodies (which store and release von Willebrand factor [VWF]), and the expression of P-selectin [22] . Platelet P-selectin is a major contributor to aggregates with leukocytes and forms bridges between leukocytes and endothelium. In fact, platelets play important roles through interactions with monocytes, neutrophils, lymphocytes, and endothelium, so platelets are the important coordinators of inflammation in sepsis [23] .
Leukocyte-derived microparticles originate from neutrophils, monocytes, and macrophages, and lymphocytes disrupt vascular homeostasis through the activity of their cytoplasmic proteins as well as bioactive lipids. An experimental model of sepsis demonstrated that inoculation with microparticles from septic rats caused increases in superoxide ion production and nuclear factor-jB activity, overexpression of inducible nitric oxide synthase, with subsequent nitric oxide overproduction, and a decrease in endothelial nitric oxide synthase activation [24] . The microparticles derived from leukocytes also play key roles in the thrombogenic reaction, and TF on vesicles is mainly associated with procoagulant activity [25] . As platelet-derived microparticles have been identified as major sources of plasma TF, further details are provided in the next section.
Consequently, an understanding of neutrophil function in clot formation is important not only for understanding the activation of the coagulation system, but also for elucidating the pathogenesis involved in inflammation and host defense.
Platelets
Platelets are critical components of thrombi, and thrombocytopenia is a frequent complication in patients with sepsis and DIC. The depletion of platelets has been recognized as a prognostic sign of increased mortality and morbidity rates. Thus, the platelet count is often used as a marker of severity in patients with sepsis; such indices include the Sequential Organ Failure Assessment (SOFA) score and the Multiple Organ Dysfunction Score. Why does the platelet count decrease during sepsis? In invertebrates, thrombocytes and phagocytes are not differentiated and hemocytes are involved in the innate immune system and thrombus formation. In this context, it is appropriate to describe a platelet as 'another leukocyte.' Platelets evolved from hemocytes, and therefore function as front-runners in the development of sepsis [26] . It is of note that platelets mediate the recruitment of leukocytes to the vascular lumen during sepsis [27] . Platelets are also known to collaborate with leukocytes in other ways. For example, platelet-activating factor (PAF) is known to be produced by a variety of cells, especially those involved in host defense, such as neutrophils, monocytes, and endothelial cells [28] . The platelets are consumed during the formation of platelet-leukocyte conjugates, and the adherence of these conjugates to the endothelium induces proinflammatory events [29] . Indeed, platelets are some of the most important components of the innate immune system, and their critical role in the propagation of inflammation should be recognized. Both the platelet count and the mean platelet volume (MPV) can indicate disease severity. An increase in size reflects the existence of a thrombotic or inflammatory milieu; thus, MPV has been suggested to be a possible marker of platelet function and activation [30] . Although the mechanism responsible for this correlation probably involves platelet production and turnover, it is not fully elucidated, as a high MPV is often seen during destructive thrombocytopenia. Therefore, one must keep in mind that sepsisassociated thrombocytopenia or changes in the MPV not only reflect disease severity, but may also contribute to the progression of sepsis and may aid in decision-making for interventions.
Platelets are also activated by VWF released from Weibel-Palade bodies, and ADAMTS-13 is the principal physiologic modulator of the size and function of VWF in plasma. In cases of acquired ADAMTS-13 deficiency represented by sepsis, ultralarge VWF multimers appear in the circulating blood, causing platelet activation and subsequent intravascular thrombus formation, which is associated with severe organ failure. Thus, secreted ADAMTS-13 activity has been reported to be associated with impaired hemostasis and organ dysfunction in patients with severe sepsis [31] . Following platelet activation, platelet-derived microparticles, which are plasma membrane submicrometer fragments with procoagulant and proinflammatory properties, are released from activated cells, and are considered to be important markers of cellular activation. Activated platelets also disseminate membrane and cytoplasmic bioactive molecules to the target cells [32] . Soriano et al. [33] measured the levels of platelet microparticles and plateletleukocyte conjugates in septic patients, and reported strong correlations between these markers and the SOFA score.
Platelets secrete > 300 active substances from their intracellular granules, and granule proteins play significant roles in both inflammation and thrombus formation. For example, a-granules contain multiple cytokines, proinflammatory and anti-inflammatory factors, and other bioactive molecules that are essential regulators of thrombus growth [34] . A recent interesting finding in this area was the upregulated secretion of high-mobility group box 1 (HMGB1) from platelets during sepsis. HMGB1 is a critical mediator for regulating platelet activation, granule secretion, adhesion, and aggregation, and its effects are mediated via a Toll-like receptor (TLR)-4/MyD88-dependent pathway. HMGB1 has also been reported to trigger neutrophil recruitment-mediated amplification of injury through the activity of its receptor, i.e. receptor for advanced glycation endproducts [35] . As platelets constitute a major source of HMGB1 within thrombi, platelet function seems to be autoregulated by this mediator [36] .
Platelet-leukocyte conjugates are important factors in disturbance of the microcirculation [33] . Apparently, platelets orchestrate pathologic immune responses and facilitate leukocyte recruitment to target tissues [37] . Platelets, as well as neutrophils and monocytes, are activated through TLR-4-ligand binding, and induce platelet binding to leukocytes, ultimately resulting in robust neutrophil activation in the form of NETs [38] .
Endothelial cells
Vascular endothelial cells are major targets of inflammatory mediators and activated neutrophils, platelets, and other cells. Opal et al. [39] suggested that 'endothelial cells are in dynamic equilibrium with a myriad of inflammatory mediators and elements of the innate immune and coagulation systems to orchestrate the host response in sepsis. The barrier function of the endothelial surface is almost uniformly impaired in septic shock, and it is likely that this contributes to adverse outcomes.' One of the most recent findings was shock-associated release of endogenous catecholamines, which contributes to endothelial disruption and injury, and hence shock-induced endotheliopathy [40] . Little is known about this potential mechanism, endothelial damage induced by endogenous catecholamines in critcal illness on this new mechanism of endothelial damage in critical illness. In the following paragraphs, we briefly summarize recent knowledge regarding the fine tuning of this delicate component.
The surface of the vascular endothelium is known to be covered by a structure called the 'glycocalyx,' and this structure regulates thrombus formation, vascular permeability, and inflammation [41] . The glycocalyx is composed of a membrane-binding domain containing core proteins (such as proteoglycan and glycoprotein conjugated with oligosaccharides) and plasma proteins (such as albumin and antithrombin) [42] (Fig. 2) . The glycocalyx is a fragile structure that resembles dense whiskers when observed under an electron microscope. The glycocalyx is synthesized by vascular endothelial cells, expressed on the endothelial cell surface, and subsequently released into the bloodstream [43] . The glycocalyx is present not only on the luminal side of the endothelial cell but also in the spaces between neighboring endothelial cells and on the side of the endothelial cell close to the basal membrane.
The glycocalyx present at this site plays an important role in the regulation of vascular permeability. Similarly, the glycocalyx surface on the basement membrane functions as a foothold for cells [44] . Unnecessary cell-cell interactions and adherence are prevented by the glycocalyx, but, because this component is quite fragile and easily destroyed, devastating disruption of the vascular glycocalyx occurs during sepsis. After the shedding of this structure, synthesis of adhesion molecules such as E-selectin and intercellular adhesion molecule 1 is initiated; these are then exposed on the cellular surface and induce the recruitment of leukocytes [45] . TF is an important mediator of thrombogenicity during sepsis. TF was previously thought to be expressed on the endothelial surface when vascular integrity was disrupted and to contribute to the thrombotic reaction during sepsis. However, this perspective has been challenged since the discovery of TF antigen in plasma, on circulating microparticles, and on leukocytes in whole blood [46] . Regardless of whether endothelial cells are major sources of TF, recombinant TF pathway inhibitor (TFPI), an analog of the physiologic inhibitor of TF, has been evaluated as a therapeutic agent [47] . Despite promising results in early clinical studies, three phase 3 trials examining recombinant TFPI for the treatment of severe sepsis failed to show a positive result [47] . The effectiveness of TFPI continues to be examined in other conditions, such as lung injury, and the reason why it is not useful in patients with sepsis should be addressed in future studies.
Another important prothrombotic factor on the endothelium is VWF, a large multimeric glycoprotein that allows the recruitment of inflammatory cells and leukocyte-platelet conjugates to the endothelium [48] . The function of VWF depends on its size and adhesive properties, which are regulated by a cleaving protease known as ADAMTS-13. Large and ultralarge VWF multimers, which are the most active forms in the promotion of platelet aggregation, are proteolytically cleaved by ADAMTS-13 [49] . During sepsis, the plasma level of VWF increases; thus, VWF is expected to be a biomarker of endothelial dysfunction [50] . ADAMTS-13 activity has been reported to decrease during sepsis, and a severe deficiency of this metalloprotease may be a concern with regard to the development of DIC [51] . Despite these important roles in the pathogenesis of sepsis, the diagnostic levels of VWF and ADAMTS-13 remain uncertain. Some authors have reported their usefulness [52] , but Hovinga et al. [53] reported that neither VWF nor ADAMTS-13 activity was correlated with disease severity, organ dysfunction, or patient outcome.
Endothelium-derived microparticles are expected to be biomarkers [54] . However, the measurement and interpretation of circulating microparticle levels is a complex task, and, in early sepsis, endothelium-derived microparticle levels increase, as activated protein C bound to microparticles retains its anticoagulant activity. Later, however, microparticles can induce deleterious changes in the expression of substances related to inflammation and oxidative stress, and they act as contributors to organ dysfunction [55] . Delabranche et al. [56] reported that endothelium-derived microparticles are useful biomarkers for the assessment of sepsis-induced DIC.
Erythrocytes
As compared with other blood cells, information on the role of erythrocytes during host defense and clot formation is still sparse. Anemia is commonly seen in sepsis patients, presumably because of the accelerated clearance of erythrocytes from circulating blood [57] . Exposure to plasma from septic patients triggers phosphatidylserine exposure on the cell membrane, which confers a procoagulant phenotype on erythrocytes in addition to fostering their phagocytosis and subsequent clearance from the circulation [57] . Erythrocytes express phosphatidylserine on their surfaces and produce thrombin through the meizothrombin pathway; meizothrombin is an intermediate between prothrombin and thrombin released from the erythrocyte surface, and participates in active clot formation [58] . Thus, erythrocytes also play a role in blood cellular immunity [59] . The theory of cellular immunity and the traditional view of its function in clot formation are now changing. Minasyan [60] noted that, during motion through the blood, erythrocytes are responsible for killing bacteria, because leukocytes cannot phagocyte bacteria at such high velocities. Erythrocytes can become charged as a result of the triboelectric effect, and this charge attracts bacteria and fixes them to the erythrocyte's surface, where they are subsequently ingested and killed.
Recent studies have reported that erythrocytes undergo an apoptosis-like cell death called eryptosis, which is characterized by cell shrinkage and phosphatidylserine externalization that leads to adherence to the vascular wall and engulfment by phagocytes equipped with phosphatidylserine receptors [61] . Eryptosis is responsible for the elimination of infected or defective erythrocytes [62] . When present in clots, erythrocytes not only function as construction materials, but also assume important roles in host defense. After incorporation into a thrombus, the erythrocytes become injured, and hemoglobin is released and oxidized, releasing free heme into the clot and circulation. Heme is a prosthetic group of hemoproteins, such as hemoglobin and myoglobin, that is crucial for oxygen transport and storage. Circulating free heme plays a bactericidal role and simultaneously induces tissue damage [63] . Thus, excess free-heme induces highly toxic events via the promotion of oxidative stress and lipid peroxidation, ultimately leading to membrane injury and cell death [64] . These events can be helpful if they only occur within a compartmentalized space, such as an immunothrombus; however, free heme can spill out of the thrombus and into the circulation [65] . Therefore, the neutralization of free heme is a possible therapy [63] . Hemopexin, a protein that scavenges free heme, reportedly protects hosts from the deleterious effects of free heme [66] . A repletion strategy for heme scavengers, such as hemopexin or haptoglobin, may be a reasonable approach [67] .
Cell death and damage-associated molecular patterns (DAMPs)
Although a variety of cell death types have been reported, a better understanding of cell death during sepsis could provide insights for the development of future therapies [68] . In the case of neutrophils, their turnover is precisely controlled to prevent unexpected host damage. The most common form of neutrophil death under both physiologic and mild inflammatory conditions is considered to be apoptosis (type I cell death) (Fig. 3) . In sepsis, the cell cycle varies remarkably, ranging from a prolongation of the lifespan to rapid neutrophil lysis after phagocytosis [69] . If this accidental cell death is triggered by by a certain stimulus, such as inflammatory and thrombotic substances, including alarmins, proteolytic enzymes and radical oxygen species are released from the necrotic cells [70] . Neutrophil oncosis and NETosis are suspected to be the major sources of alarmins during infection [71] . NETosis plays a crucial role in the pathogenesis of sepsis. The levels of circulating neutrophil proteases and cell-free DNA are increased and significantly correlate with each other [72] . In addition, the levels of both markers increase with severity and outcome [72] . Neutrophil activation in the form of NETs is mainly focused on preventing the spread of invading pathogens and killing them, and coagulation activation induced by NETs contributes to walling off of bacteria in order to limit their spread [14] . The nucleosome levels in septic patients showed a significant correlation with the presence of neutrophilic proteases in the circulation, pointing to NETs as a possible source of the nucleic substances [73] .
Many other types of cell death that cause systemic inflammation exist. One type that is similar to oncosis but is programmed is known as necroptosis (type III cell death). Necroptosis is a proinflammatory form of cell death that is dependent on receptor interacting protein-1 kinase (RIP1K) and leads to necrotic cell lysis [74] . Pyroptosis operates to remove the replication niche of intracellular pathogens, making them susceptible to phagocytosis; however, the overwhelmed activation of pyroptosis can contribute to the systemic propagation of inflammatory reactions [75] . Pyroptosis is induced through the caspasedependent pathway, and leads to necrotic cell death [76] . undergo rapid cell death that depends on RIP1K [77] . A significant proportion of inflammatory substances are released upon the above-mentioned types of cell death, and these substances promptly become ligated to their receptors, which are known as pattern recognition receptors (PRRs) [78] . As mentioned before, TLRs, which are the most well known PPRs, are key regulators of cellular functions and intravascular immunity [79] . Numerous other, as yet unknown, types of cell death might be involved in the regulation of host inflammation and the coagulation system. DAMPs are known to play a critical role in worsening of the clinical condition in sepsis [80] . Here, we will not devote much space to humoral mediators, such as cytokines, chemokines, and complement, but instead will focus on cellular components from injured cells. In the past, pathogen-associated molecular patterns (PAMPs) and the host immune response to PAMPs were the main foci of research. PAMPs are exogenous substances associated with pathogens that are recognized by PRRs and initiate the production of immune-related proteins, such as proinflammatory cytokines and chemical mediators [81] . If the damage is severe enough, endogenous proteins known as 'alarmins,' which include the expression of HMGB1 and heat shock proteins, leak out and exacerbate the damage [82] . According to the European Molecular Biology Organization 2006 [81] , alarmins are defined as factors that: (i) are rapidly released by cells that have undergone necrosis; (ii) activate innate immune responses through their ligation to receptors; (iii) are actively secreted by activated immune cells; and (iv) are endogenous substances associated with the repair of tissues damaged by invasion and inflammation, and with the maintenance of homeostasis. There is increasing interest in sepsis-associated cell deathrelated nucleic substances, such as DNA, nucleosomes, and histones, and inflammatory mediators from organelles in the cytosol, namely mitochondrial DNA and ATP. DNA in plasma samples from patients with sepsis reportedly showed a positive correlation with thrombin generation, and the addition of DNase to the sample attenuated thrombin generation [83] . Other than neutrophils, monocytes and endothelial cells release DNA and other nucleus-related components upon activation or cellular damage. Together with PAMPs, these alarmins are known as DAMPs, and constitute a focus of intensive research at present [84] .
Therapeutic strategies

Anticoagulants
It is widely accepted that coagulation activation in sepsis induces microvascular thrombosis, leading to multiple organ dysfunction, and the severity of coagulopathy is known to be directly correlated with mortality [3] . In septic patients, the levels of physiologic anticoagulants are decreased, although restoring anticoagulant activity continues to be a theraputic strategy, and, as recommended in the latest Clinical Practice Guidelines for the Management of Sepsis and Septic Shock from Japan (J-SSCG; http://www.jaam.jp/html/info/2016/pdf/ J-SSCG2016_ver2.pdf#search=%27Japanese+Clinical+ Practice+Guidelines+for+Management+of+Sepsis+a nd+Septic+Shock%27), is being considered as a therapeutic target in patients with DIC. However, to date, none of the anticoagulants have been proven to be effective worldwide. Recombinant activated protein C was approved by the Food and Drug Administration and the European Medicines Agency at one time, but was later withdrawn from the worldwide market after the completion of a randomized controlled trial (RCT) [85] . This RCT could not show a survival benefit of recombinant activated protein C in septic shock patients. Antithrombin was also expected to be useful, but it failed to show any efficacy in an RCT [86] .
Antithrombin acts as the predominant thrombin inhibitor on the vascular surface through glycosaminoglycan binding. However, its clinical usefulness has not been proven in a sufficiently powered RCT. Glycosaminoglycans, which are the major components of the glycocalyx, are heparin-like molecules that contribute to the antithrombotic capacity on the endothelium [87] . Although > 90% of antithrombin concentrate is composed of a-antithrombin, b-antithrombin has been shown to protect endothelial cells more efficiently than a-antithrombin [88] . We speculate that a b-isoform-rich antithrombin formula might act more efficiently than commercially available antithrombin concentrates.
Recombinant thrombomodulin is another therapeutic option. Thrombomodulin on the endothelial cell surface is known to be significantly downregulated during sepsis. Recombinant thrombomodulin has been constructed, and has been clinically available for the treatment of DIC in Japan since 2008; it is also being investigated for the treatment of sepsis in the USA and other countries [89] . The effect of this anticoagulant on SIC is currently under investigation in a multinational phase 3 trial, and the results of this trial will be available in late 2018.
Antiplatelet agents
Although platelet activation, aggregation and composite thrombus formation with leukocytes are crucial events during sepsis, attempts to suppress platelet activation have not yielded a favorable effect. Antiplatelet therapy with the enzyme PAF acetylhydrolase (PAF-AH) was examined previously [90] . PAF-AH degrades PAF, and therefore was expected to be useful as a treatment for severe sepsis. However, a clinical trial failed to show an effect on 28-day all-cause mortality. Similarly, neither a PAF antagonist [91] nor a PAF receptor antagonist [92] was successful in clinical trials.
Anti-TLR-4 agents
A trial using the TLR-4 blocker eritoran, a synthetic lipid A antagonist that blocks lipopolysaccharide from binding to the TLR-4 receptor on cell surfaces, was performed. However, this compound failed to show any efficacy [93] . Similarly, TAK-242, a TLR-4-mediated signaling inhibitor, was studied in a phase 2 trial; the 28-day mortality rates were 24% in the placebo group, 22% in the low-dose TAK-242 group, and 17% in the high-dose TAK-242 group (P = 0.26 for placebo versus high dose) [94] . Although a trend towards a reduction in mortality was observed, efforts to develop these two TLR-4 inhibitors have been discontinued, because the expected improvements were not achieved.
Anti-alarmins
Alarmins are important targets for the treatment for sepsis. Several plasma proteins, such as albumin and activated protein C, are known to be capable of attenuating the toxicity of circulating histones [95] ; however, significant decreases in the levels of these proteins are seen during sepsis. Pentraxin 3 (PTX3) is another plasma protein that coaggregates with histones, thereby protecting endothelial cells from toxicity [96] . Interestingly, C-reactive protein, a member of the short pentraxin subfamily, attenuates histone toxicity in a similar manner. PTX3 families are candidates for development as therapeutic agents. Other than these naturally derived plasma proteins, heparins have been reported to neutralize the cytotoxicity of histones through high-affinity electrostatic interactions [97] .
Hemoadsorption
The adsorption of activated blood cells could be another strategy. One approach is the use of a polymyxin B-immobilized fiber column (PMX). Although the primary effect of this device is the adsorption of lipopolysaccharide from the circulating blood, it has also been reported that the PMX can trap activated leukocytes and platelets [98] . In this context, the elimination of endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol generated by activated macrophages and platelets, can be expected [99] . Cannabinoids are known to facilitate endotoxic shock and play a critical role in the induction of shock-related hypotension. The clinical benefit of hemoadsorption with the PMX is still under discussion; however, a recent metaanalysis has suggested its efficacy for patients with septic shock [100] . Currently, a multicenter, placebo-controlled trial is underway in 50 ICUs in the USA and Canada. The results will be presented in late 2017.
Conclusion
Recent studies have shown that thrombus formation not only plays a role in hemostasis, but also contributes to innate immunity. Currently, intravascular coagulation and thrombus formation are widely recognized as immunothrombosis. Leukocytes are the major cellular components involved in the initiation and propagation of thrombus formation. Not only monocytes but also neutrophils have evolved cell-specific mechanisms to potentiate coagulation through multimodalities such as expressing TF, releasing alarmins and microparticles, and ejecting NETs. Together with leukocytes, platelets are among the first cells that encounter the sites of infection and, in concert with fibrin, form clots for the front line of host defense. It is a well-known fact that platelets and the coagulation cascade communicate and mutually support each other. In addition to this classic mechanism, recent studies have elucidated the important roles of platelet-derived microparticles and secreted nuclear substances such as DNA, histones, and HMGB1. The activated leukocytes and platelets and their conjugates damage the fine lining of the endothelium termed the glycocalyx, which is one of the most important antithrombotic systems, and convert its character to procoagulant. The growing thrombus involves erythrocytes, which also induce procoagulant activity by expressing meizothrombin and further increasing clotting power.
In summary, inflammation and coagulation are inextricably linked and contribute to the pathophysiology of sepsis. As thrombus formation is one component of essential host defense mechanisms, it represents a potential target for therapy. However, we still do not know when, in whom, to what degree or how to manage it. Approaches using various anticoagulants, regulators of cell activation and anti-DAMPs have revealed that some of these strategies are potentially effective; however, our knowledge remains extremely sparse in this field. Much attention should be directed worldwide to therapies that modulate coagulation and inflammation. 
